# Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients

> **NCT01276899** · — · COMPLETED · sponsor: **Jewish General Hospital** · enrollment: 80 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **PROCEDURE:** Needle core biopsies
- **PROCEDURE:** Needle core biopsies of metastatic lesion

## Key facts

- **NCT ID:** NCT01276899
- **Lead sponsor:** Jewish General Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2015-09
- **Final completion:** —
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2022-06-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01276899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01276899, "Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01276899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*